Though usually harmless, some types of HPV cause cervical lesions that, over a period of time, can develop into cancer if untreated. The majority of women with an HPV infection will not develop cervical cancer, but regular screening is crucial. In most cases cervical cancer can be prevented through early detection and treatment of abnormal cell changes that occur in the cervix years before cervical cancer develops. These changes are typically detected through a Pap test. When a female gets Pap test, she is being screened for to make sure that there are no abnormal or precancerous changes in the cells on her cervix. If the Pap test results show these cell changes, this is usually called cervical dysplasia. Other common terms the healthcare provider may use include:
- Abnormal cell changes
- Precancerous cells changes
- CIN (cervical intraepithelial neoplasia)
- SIL (squamous intraepithelial lesions)
- “Warts” on the cervix
All of these terms mean similar things – it simply means that abnormalities were found. Most of the time, these cell changes are due to HPV. There are many types of HPV that can cause cervical dysplasia. Most of these types are considered “high-risk” types, which means that they have been linked with cervical cancer. Just because a female has cervical dysplasia, it does not mean she will get cervical cancer. It means that her healthcare provider will want to closely monitor her cervix every so often – and possibly do treatment – to prevent further cell changes that could become cancerous over time if left unchecked. Cervical cancer is a slow-growing condition that usually takes years to progress. This is why getting screened on a regular basis is important; screening can catch any potential problems before they progress.
- If a Pap test is used alone, screening should be done every three years.
- If a combination Pap-HPV DNA test is used (only approved for women over age 30) and the result is normal/negative, then screening should be done once every five years.
- In some situations healthcare providers may also use a “genotyping” test that checks specifically for the HPV types found in most cervical cancers. If you have questions about which tests are right for you, ask your healthcare provider.
- Even though screening for cervical cancer can occur less often, it is still important for you to see your healthcare provider annually for other female-related health care needs—ask your provider what he or she recommends.
- Try to schedule the test on a day when you do not expect to be on your menstrual period. If your period begins unexpectedly and will be continuing on the day of your test, try to reschedule the appointment.
- Avoid sexual intercourse 48 hours before the test.
- Do not douche 48 hours before the test.
- Do not use tampons, or vaginal creams, foams, films, or jellies (such as spermicides or medications inserted into the vagina) for 48 hours before the test
Degrees of Severity:
- Mild dysplasia
- Moderate dysplasia
- Severe dysplasia
Degrees of Severity:
- CIN 1
- CIN 2
- CIN 3
*CIN stands for cervical intraepithelial neoplasia
Bethesda System (2001)
Degrees of Severity:
- ASC-US (Atypical Squamous Cells of Undetermined Significance): Means the results look borderline between “normal” and “abnormal” – often not HPV-related
- ASC-H (Atypical Squamous Cells-can not exclude HSIL): Borderline results, but may really include High-Grade lesions
- Low-Grade SIL (LSIL): SIL stands for squamous intraepithelial lesion
- High-Grade SIL (HSIL)
Degrees of Severity:
- Class 1
- Class 2
- Class 3
- Class 4
The class system is no longer widely used. Women with abnormal Pap test results are usually examined further for cervical problems. This may involve coming back for a colposcopy and biopsy, or coming back in a few months for another Pap test. If the Pap result is “ASC-US,” then a HPV-DNA test may be done in the lab to see whether HPV is causing this borderline “normal-abnormal” Pap result.
- The digene Hybrid Capture II ™ HPV test, produced by Qiagen
- The Hologic/Gen-Probe Corporation’s Cervista™ HPV High-Risk (HR) test
- The Hologic/Gen-Probe Corporation’s Cervista® HPV 16/18 test
- The Roche cobas® HPV test
- The APTIMA® HPV mRNA Assay, produced by Hologic/Gen-Probe
- As part of a Pap/HPV co-test in women age 30 and older
- When a Pap test is unclear, to see if HPV is present
Recently the cobas® test was approved for use with women age 25 and older for primary cervical cancer screening, followed by a Pap test for women with certain results. Don’t worry about which option is the best one for you: the exact test or tests used is not as important as simply being screened regularly! Your healthcare provider will help you sort out which option is right for you.
- If the Pap result shows dysplasia or precancerous changes. This is because these cell changes are almost always associated with HPV.
- As part of a Pap/HPV co-test in women under age 30
- The HPV test is not approved for use with males. It is only FDA approved to be used on the female’s cervix.
- location of the abnormal cells
- size of the lesions on the cervix
- degree or severity of the Pap test results
- degree or severity of the colposcopy and biopsy results
- HPV test results (if this test was needed)
- age and pregnancy status
- previous treatment history
- patient and healthcare provider preferences
There are a variety of treatments for cervical dysplasia:
- Cryotherapy (freezing the cells with liquid nitrogen)
- LEEP (Loop Electrosurgical Exision Procedure)
- Conization (also called cone biopsy)
- Laser (not as widely used today due to high cost, lack of availability, and not all doctors are well-trained with using it. LEEP is more commonly used)
- No treatment at all since even mild abnormal cell changes may resolve without treatment. The healthcare provider may just monitor the cervix by either doing a colposcopy, repeat Pap testing, or a test for HPV.
- Anal cancer is a rare occurrence that has been strongly linked to “high-risk” types of HPV.
- Abnormal cell changes in the anal area (anal dysplasia or anal neoplasia) are more common among individuals who engage in receiving anal sex.
- Anal cancer rates in men who have sex with men are 17-fold higher than in the general population. However, anal dysplasia has also been reported in some females who have a history of severe cervical dysplasia.
- Treatment is available for anal dysplasia and anal cancer.
Head and neck cancer:
- “High risk” HPV is linked with some types of head and neck cancer, primarily oropharyngeal cancers found in the base of the tongue, tonsils, and soft palate.
- Oral sex may be a risk factor for acquiring oral HPV.
- While HPV is very common, oropharyngeal cancers are rare. Most of these cancers are not related to HPV.
Penile Intraepithelial Neoplasia (PIN) and penile cancer:
- Cancer of the penis is extremely rare in the United States, and HPV is not always the cause.
- There are some cases of cell changes (neoplasia) on the penis, which are caused by “high-risk” types of HPV.
- Most males do not ever experience symptoms or health risks if they get one or more “high-risk” types of HPV.
- Penile neoplasia can be treated. There is not a cancer screening for the penis because cancer of the penis is extremely rare, and because it is difficult to get a good cell sample from the penis.
Vaginal Intraepithelial Neoplasia (VAIN) and vaginal cancer:
- HPV has been linked with some, but not all, cases of cell changes in the vagina and with vaginal cancers.
- Various treatment options are available for vaginal neoplasia, depending on how mild or severe the cell changes are in this area.
- Vaginal cancers are rare.
Vulvar Intraepithelial Neoplasia (VIN) and vulvar cancer:
- HPV has been linked with some, but not all, cases of cell changes on the vulva (outside female genital area) and with vulvar cancers.
- Various treatment options are available for vulvar neoplasia, depending on how mild or severe the cell changes are in this area.
- Vulvar cancers are rare.
- Abstinence (not having any kind of sex with anyone)
- Having sex only with one partner who has sex only with you. People who have many sex partners are at higher risk of getting other sexually transmitted infections (STIs).
- If someone currently has abnormal cell changes, he or she should not have sexual activity until after the cells have been treated or have self resolved. This may help to lower the risk of transmission.
- Condoms used the right way from start to finish each time of having sex may help provide minimal protection – but only for the skin that is covered by the condom. Condoms do not cover all genital skin, so they don’t give 100% protection.
- Spermicidal foams, creams, jellies (and condoms coated with spermicide) are not proven to be effective in preventing HPV and may cause microscopic abrasions that make it easier to contract STIs. Spermicides are not recommended for routine use.
- If someone was exposed to the types of HPV that can cause abnormal cell changes, it would be unlikely that he or she will become re-infected with those same types since immunity will be set-up at some point.
- Realize that most people are exposed to one or more HPV types in their lifetime, and most will never even know it because they will not have visible symptoms.
- It is important for partners to understand the “entire picture” about HPV so that both people can make informed decisions based on facts, not fear or misconceptions.